Healthcare provider profile · identity verified

Susan Moyer, MD

Internal Medicine · WARMINSTER, PA · NPI 1396798740

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	353	115
Levothyroxine Sodium	Levothyroxine Sodium	327	108
Amlodipine Besylate	Amlodipine Besylate	279	77
Eliquis	Apixaban	257	44
Simvastatin	Simvastatin	215	62
Losartan Potassium	Losartan Potassium	209	58
Lisinopril	Lisinopril	189	55
Gabapentin	Gabapentin	182	57
Omeprazole	Omeprazole	168	59
Furosemide	Furosemide	163	44
Rosuvastatin Calcium	Rosuvastatin Calcium	151	42
Metoprolol Succinate	Metoprolol Succinate	149	50
Pantoprazole Sodium	Pantoprazole Sodium	125	39
Tramadol Hcl	Tramadol Hcl	115	39
Escitalopram Oxalate	Escitalopram Oxalate	112	35
Metoprolol Tartrate	Metoprolol Tartrate	111	19
Atenolol	Atenolol	105	24
Lorazepam	Lorazepam	104	30
Tamsulosin Hcl	Tamsulosin Hcl	101	29
Alendronate Sodium	Alendronate Sodium	96	29
Hydrochlorothiazide	Hydrochlorothiazide	95	32
Sertraline Hcl	Sertraline Hcl	92	23
Trazodone Hcl	Trazodone Hcl	90	22
Finasteride	Finasteride	83	23
Pravastatin Sodium	Pravastatin Sodium	80	27
Clopidogrel	Clopidogrel Bisulfate	76	22
Arexvy	Rsvpref3 Antigen/As01e/Pf	73	73
Carvedilol	Carvedilol	73	28
Allopurinol	Allopurinol	70	17
Famotidine	Famotidine	66	23
Mirtazapine	Mirtazapine	65	15
Metformin Hcl	Metformin Hcl	64	21
Alprazolam	Alprazolam	62	27
Duloxetine Hcl	Duloxetine Hcl	55	13
Potassium Chloride	Potassium Chloride	53	17
Ezetimibe	Ezetimibe	40	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	38	32
Januvia	Sitagliptin Phosphate	38	suppressed
Abrysvo	Rsv Vacc, Pref A And Pref B/Pf	36	36
Valsartan	Valsartan	36	11
Venlafaxine Hcl Er	Venlafaxine Hcl	36	suppressed
Xarelto	Rivaroxaban	33	suppressed
Donepezil Hcl	Donepezil Hcl	31	suppressed
Montelukast Sodium	Montelukast Sodium	31	12
Oxycodone Hcl	Oxycodone Hcl	31	11
Bupropion Hcl Sr	Bupropion Hcl	30	suppressed
Citalopram Hbr	Citalopram Hydrobromide	28	suppressed
Hydralazine Hcl	Hydralazine Hcl	27	11
Triamcinolone Acetonide	Triamcinolone Acetonide	27	suppressed
Enalapril Maleate	Enalapril Maleate	26	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	26	suppressed
Temazepam	Temazepam	26	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	25	suppressed
Celecoxib	Celecoxib	24	suppressed
Digoxin	Digoxin	24	suppressed
Fluticasone Propionate	Fluticasone Propionate	23	12
Levetiracetam	Levetiracetam	23	suppressed
Azithromycin	Azithromycin	22	22
Glimepiride	Glimepiride	22	suppressed
Myrbetriq	Mirabegron	21	suppressed
Folic Acid	Folic Acid	20	suppressed
Clonazepam	Clonazepam	19	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	19	suppressed
Memantine Hcl	Memantine Hcl	19	suppressed
Nystatin	Nystatin	19	11
Synthroid	Levothyroxine Sodium	19	suppressed
Acyclovir	Acyclovir	18	suppressed
Raloxifene Hcl	Raloxifene Hcl	18	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	17	suppressed
Lithium Carbonate	Lithium Carbonate	17	suppressed
Metformin Hcl Er	Metformin Hcl	17	suppressed
Methimazole	Methimazole	17	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	17	suppressed
Venlafaxine Hcl	Venlafaxine Hcl	17	suppressed
Warfarin Sodium	Warfarin Sodium	17	suppressed
Latanoprost	Latanoprost	16	suppressed
Multaq	Dronedarone Hcl	16	suppressed
Spironolactone	Spironolactone	16	suppressed
Bupropion Hcl	Bupropion Hcl	15	suppressed
Entresto	Sacubitril/Valsartan	15	suppressed
Meloxicam	Meloxicam	15	suppressed
Prednisone	Prednisone	15	suppressed
Methylprednisolone	Methylprednisolone	14	13
Buspirone Hcl	Buspirone Hcl	13	suppressed
Pregabalin	Pregabalin	13	suppressed
Cholestyramine	Cholestyramine (With Sugar)	12	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	12	suppressed
Estradiol	Estradiol	12	suppressed
Mycophenolate Mofetil	Mycophenolate Mofetil	12	suppressed
Solifenacin Succinate	Solifenacin Succinate	12	suppressed
Terazosin Hcl	Terazosin Hcl	12	suppressed
Aripiprazole	Aripiprazole	11	suppressed
Breo Ellipta	Fluticasone/Vilanterol	11	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	11	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	11	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	11	suppressed
Paricalcitol	Paricalcitol	11	suppressed
Ramipril	Ramipril	11	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error